MYocarditis and/or Pericarditis Following mRNA COVID-19 VACCination National Surveillance Study
Conditions: Myocarditis; Myocarditis Acute; Pericarditis; Pericarditis Acute Interventions: Diagnostic Test: Stand of care ECG, Holter, MRI, ECHO, Quality of life questionnaire; Other: Baseline Quality of Life questionnaire Sponsors: Cardiology Research UBC Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - October 26, 2023 Category: Research Source Type: clinical trials
Moderna Announces First Participant Dosed in Phase 3 Study of mRNA-1083, a Combination Vaccine Against Influenza and COVID-19
mRNA-1083 is Moderna ' s first respiratory combination vaccine candidate to enter a Phase 3 trial
Phase 3 initiation follows data from a Phase 1/2 trial where mRNA-1083 showed strong immunogenicity against influenza and COVID-19, with an acceptable... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - October 24, 2023 Category: Pharmaceuticals Source Type: clinical trials
A Study of mRNA-1083 (SARS-Cov-2 and Influenza) Vaccine in Healthy Adult Participants, ≥50 Years of Age
Conditions: SARS-CoV-2; Influenza Interventions: Biological: mRNA-1083; Biological: Placebo; Biological: Influenza Vaccine; Biological: COVID-19 Vaccine Sponsors: ModernaTX, Inc. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - October 24, 2023 Category: Research Source Type: clinical trials
Immunogenicity of Concomitant Administration of COVID-19 Vaccines With Influenza Vaccines
Conditions: COVID-19; Influenza; Vaccine Reaction; Contaminant Injected Interventions: Biological: Omicron-containing COVID-19 vaccine; Biological: influenza vaccine Sponsors: Catholic Kwandong University; Korea University Guro Hospital Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - October 19, 2023 Category: Research Source Type: clinical trials
ACTIVATE in Public Housing
Conditions: Pneumonia; Influenza; Varicella Zoster; Meningitis; COVID-19; Vaccine Hesitancy Interventions: Behavioral: Increasing Willingness and Uptake of Influenza, Pneumonia, Meningitis, HZV, and COVID-19 Vaccination Sponsors: Charles Drew University of Medicine and Science Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - October 10, 2023 Category: Research Source Type: clinical trials
Equity Evaluation of Fact Boxes on Informed COVID-19 and Influenza Vaccination Decisions - Study Protocol
Conditions: COVID-19; Influenza Interventions: Other: Fact box Sponsors: Harding Center for Risk Literacy Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - October 10, 2023 Category: Research Source Type: clinical trials
Prospective Biological Study to Evaluate the Persistence of COVID-19 Vaccine and Other Vaccines'-Induced Immune Responses in Follicular Lymphoma Patients Undergoing Frontline Induction Immuno-chemotherapy and Anti-CD20 Maintenance
Conditions: Follicular Lymphoma Interventions: Diagnostic Test: Cellular immunity vs SARS-CoV-2; Diagnostic Test: Humoral immunity vs SARS-CoV-2; Diagnostic Test: Cellular immunity vs Varicella Zoster Virus; Diagnostic Test: Humoral immunity vs Varicella Zoster Virus; Diagnostic Test: Diphtheria toxin-binding IgG; Diagnostic Test: Tetanus toxoid-binding IgG; Diagnostic Test: T-cell populations and markers characterization Sponsors: Fondazione Italiana Linfomi - ETS Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - October 6, 2023 Category: Research Source Type: clinical trials
Study of the Vector Vaccine GamCovidVac-M (Altered Antigenic Composition)
Conditions: COVID-19 Interventions: Biological: GamCovidVac-M vector vaccine for the prevention of COVID-19 with altered antigenic composition Sponsors: Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - October 5, 2023 Category: Research Source Type: clinical trials
Study of the Vector Vaccine GamCovidVac for the Prevention of COVID-19 With Altered Antigenic Profile With Participation of Adult Volunteers
Conditions: COVID-19 Interventions: Biological: GamCovidVac vector vaccine for the prevention of COVID-19 (with altered antigenic profile) Sponsors: Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - October 5, 2023 Category: Research Source Type: clinical trials
Bacillus Calmette-Gu érin vaccination as defense against SARS-CoV-2 (BADAS): a randomized controlled trial to protect healthcare workers in the USA by enhanced trained immune responses
DiscussionIt is expected this trial will allow evaluation of the effects of BCG vaccination at a population level in high-risk healthcare individuals through a mitigated clinical course of SARS-CoV-2 infection and inform policy making during the ongoing epidemic.Trial registrationClinicalTrials.gov NCT04348370. Registered on April 16, 2020. (Source: Trials)
Source: Trials - October 4, 2023 Category: Research Source Type: clinical trials
Novavax 2023-2024 COVID-19 Vaccine Now Authorized and Recommended for Use in the U.S.
GAITHERSBURG, Md., Oct. 3, 2023 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its novel Matrix-M™ adjuvant, today announced that the Novavax COVID-19 Vaccine, Adjuvanted (2023-2024... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - October 3, 2023 Category: Pharmaceuticals Source Type: clinical trials
The Efficacy of the 2023-2024 Updated COVID-19 Vaccines Against COVID-19 Infection
Conditions: COVID-19; Vaccine-Preventable Diseases; SARS CoV 2 Infection; Upper Respiratory Tract Infection; Upper Respiratory Disease Interventions: Biological: Novavax COVID-19 vaccine (2023-2024 formula XBB containing); Biological: Pfizer COVID-19 mRNA vaccine (2023-2024 formula XBB containing) Sponsors: Sarang K. Yoon, DO, MOH; Westat; Novavax Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - October 3, 2023 Category: Research Source Type: clinical trials
Study Will Assess the Safety, Neutralizing Activity and Efficacy of AZD3152 in Adults With Conditions Increasing Risk of Inadequate Protective Immune Response After Vaccination and Thus Are at High Risk of Developing Severe COVID-19
Condition: COVID-19, SARS-CoV-2 Interventions: Biological: Biological: AZD3152; Biological: Biological: Placebo Sponsor: AstraZeneca Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 27, 2023 Category: Research Source Type: clinical trials
Study of " Sputnik Lite " for the Prevention of COVID-19 With Altered Antigenic Composition.
Condition: COVID-19 Intervention: Biological: " Sputnik Lite " vaccine for the prevention of COVID-19 with altered antigenic composition Sponsor: Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 27, 2023 Category: Research Source Type: clinical trials
Study of " Sputnik Lite " for the Prevention of COVID-19 With Altered Antigenic Composition.
Conditions: COVID-19 Interventions: Biological: " Sputnik Lite " vaccine for the prevention of COVID-19 with altered antigenic composition Sponsors: Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 27, 2023 Category: Research Source Type: clinical trials
